Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2015 Elsevier Ltd All rights reserved. There has been a marked change in the therapeutics available to patients. In the past century, these were nearly all small-molecule chemicals, absorbable via the gut. Now, since the late 1990s, there is a major alternative, monoclonal antibodies and antibody-like fusion proteins. This chapter summarizes the research that led to defining tumor necrosis factor, TNF, as a therapeutic target for rheumatoid arthritis and its therapeutic success that changed the perception of antibodies as therapeutics.

Original publication

DOI

10.1016/B978-0-12-397933-9.00029-1

Type

Chapter

Book title

Molecular Biology of B Cells: Second Edition

Publication Date

15/12/2014

Pages

541 - 547